Market Reports Center

Global Cardiac Biomarkers Market 2017-2021


Report Details

Global Cardiac Biomarkers Market 2017-2021

SKU TCOCT171366
Category Medical Devices
Publisher Technavio
Pages 96
Published Oct-17
Request Discount Pay by Wire/Invoice

Description

Technavio Announces the Publication of its Research Report – Global Cardiac Biomarkers Market 2017-2021

Technavio recognizes the following companies as the key players in the global cardiac biomarkers market: Abbott, Alere, and F. Hoffmann-La Roche.

Other Prominent Vendors in the market are: Advanced ImmunoChemical, AgPlus Diagnostics, AZSense, BD, BG Medicine, BioLegend, bioMérieux, Bio-Rad Laboratories, BODITECH MED, CAVADIS, Cisbio Bioassays, Creative Diagnostics, Critical Diagnostics, Cruinn Medical, DiaDexus, Enzo Life Sciences, Lepu Medical, LifeSign, LSI Medience, Merck, Monobind, Myriad RBM, NeoClone, NOWDiagnostics, Olink, Randox Laboratories, Response Biomedical, Signosis, Thermo Fisher Scientific, Tosoh Europe, Trinity Biotech, Trivitron Healthcare, and Wondfo.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is increased clinical trials. There is an increasing number of clinical trials for cardiac biomarkers. Manufacturers, universities, and research institutes are conducting various clinical trials to prove the efficacy of cardiac biomarkers. The increase in proficiency and accurate results of the cardiac biomarkers provide a high demand for them in the market.”

According to the report, one driver in the market is increasing use of cardiac biomarkers. The use of cardiac biomarkers helps in assessing the risk associated with diabetes, which invariably affects the cardiovascular system of the individual. It also helps in providing the rapid and accurate diagnosis for critically ill patients with presumed ACS. This induces the high adoption of cardiac biomarkers among the end-users to treat people with various cardiac diseases. Based on the study conducted by Universidade Federal do Rio Grande do Sul and associated hospitals in 2017, the people with type 2 diabetes are observed to be having cardiovascular risks as well.

Further, the report states that one challenge in the market is dominance of top vendors. The high market share of the top players such as Abbott, Alere, and F. Hoffmann La-Roche creates a market barrier for the small companies as well as the startups. There is a tendency of small start-ups getting acquired by the top manufacturers, which prevents them from establishing their business in the market. The hurdles faced by the small market players and the start-ups are mainly the budget constraints, innovative products, less number of clinical trials to prove the efficiency of the product, and brand image.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
About Cardiac Biomarkers

Cardiac biomarkers are the substances used to detect the risk stratification of a patient with chest pain or suspected acute coronary syndrome (ACS). These biomarkers are released in blood when the heart is damaged or stressed. The tests that are carried out by introducing the cardiac biomarkers to the bloodstream help in determining the risks of associated heart conditions such as cardiac ischemia, ACS, myocardial infarction, and other associated heart diseases.

Technavio’s analysts forecast the global cardiac biomarkers market to grow at a CAGR of 12.97% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global cardiac biomarkers market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Cardiac Biomarkers Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Abbott
• Alere
• F. Hoffmann-La Roche

Other prominent vendors
• Advanced ImmunoChemical
• AgPlus Diagnostics
• AZSense
• BD
• BG Medicine
• BioLegend
• bioMérieux
• Bio-Rad Laboratories
• BODITECH MED
• CAVADIS
• Cisbio Bioassays
• Creative Diagnostics
• Critical Diagnostics
• Cruinn Medical
• DiaDexus
• Enzo Life Sciences
• Lepu Medical
• LifeSign
• LSI Medience
• Merck
• Monobind
• Myriad RBM
• NeoClone
• NOWDiagnostics
• Olink
• Randox Laboratories
• Response Biomedical
• Signosis
• Thermo Fisher Scientific
• Tosoh Europe
• Trinity Biotech
• Trivitron Healthcare
• Wondfo

Market driver
• Increasing use of cardiac biomarkers
• For a full, detailed list, view our report

Market challenge
• Dominance of top vendors
• For a full, detailed list, view our report

Market trend
• Increased clinical trials
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


News/Press Release

Table of Content

Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 06: Market segmentation by technology
• Market overview
• Conventional laboratory testing
• POC testing
PART 07: Market segmentation by product
• Market overview
• Global troponin (cTnI, cTnT) assay market
• Global others assay market
• Global BNP & NT-proBNP assay market
• Global CK-MB assay market
• Global myoglobin assay market
PART 08: Market segmentation by end-user
• Market overview
• Hospitals and clinics
• Diagnostic laboratories
PART 09: Geographical segmentation
• Market overview
• Cardiac biomarkers market in Americas
• Cardiac biomarkers market in EMEA
• Cardiac biomarkers market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Market challenges
PART 12: Market trends
• Increased clinical trials
• Increasing use of cardiac biomarkers in POC testing
• Emerging cardiac biomarkers
PART 13: Vendor landscape
• Competitive landscape
• Abbott
• Alere
• F. Hoffmann-La Roche
• Key companies to watch
• Other prominent vendors
PART 14: Appendix
• List of abbreviations
?
List of Exhibits
Exhibit 01: Advantages associated with cardiac biomarkers
Exhibit 02: Market overview of global cardiac biomarkers market 2016
Exhibit 03: Global cardiac biomarkers market 2016-2021 ($ millions)
Exhibit 04: Five forces analysis
Exhibit 05: Overview of global cardiac biomarkers market by technology 2016
Exhibit 06: Global cardiac biomarkers market by conventional laboratory testing 2016-2021 ($ millions)
Exhibit 07: Global cardiac biomarkers market by POC testing 2016-2021 ($ millions)
Exhibit 08: Overview of global cardiac biomarkers market by product 2016
Exhibit 09: Global troponin (cTnI, cTnT) assay market 2016-2021 ($ millions)
Exhibit 10: Global others assay market 2016-2021 ($ millions)
Exhibit 11: Global BNP & NT-proBNP assay market 2016-2021 ($ millions)
Exhibit 12: Global CK-MB assay market 2016-2021 ($ millions)
Exhibit 13: Global myoglobin assay market 2016-2021 ($ millions)
Exhibit 14: Overview and strategy of global cardiac biomarkers market by end-users 2016
Exhibit 15: Buying criteria of end-users in global cardiac biomarkers market 2016
Exhibit 16: Global cardiac biomarkers market by geography 2016 and 2021
Exhibit 17: Overview of cardiac biomarkers market in Americas
Exhibit 18: Cardiac biomarkers market in Americas 2016-2021 ($ millions)
Exhibit 19: Overview of cardiac biomarkers market in EMEA
Exhibit 20: Cardiac biomarkers market in EMEA 2016-2021 ($ millions)
Exhibit 21: Overview of cardiac biomarkers market in APAC
Exhibit 22: Cardiac biomarkers market in APAC 2016-2021 ($ millions)
Exhibit 23: Market analysis for the increasing cardiac diseases worldwide
Exhibit 24: Average cost of cardiac biomarkers
Exhibit 25: Clinical trials and their impact
Exhibit 26: Competitive structure analysis of global cardiac biomarkers market 2016
Exhibit 27: Market penetration of various cardiac biomarkers providers 2016
Exhibit 28: Strategic success factors of companies in global cardiac biomarkers market 2016
Exhibit 29: Abbott: Strength assessment
Exhibit 30: Abbott: Strategy assessment
Exhibit 31: Abbott: Opportunity assessment
Exhibit 32: Alere: Strength assessment
Exhibit 33: Alere: Strategy assessment
Exhibit 34: Alere: Opportunity assessment
Exhibit 35: F. Hoffmann-La Roche: Strength assessment
Exhibit 36: F. Hoffmann-La Roche: Strategy assessment
Exhibit 37: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 38: Danaher: Company assessment
Exhibit 39: Siemens: Company assessment

Companies Profiled

Abbott, Alere, F. Hoffmann-La Roche, Advanced ImmunoChemical, AgPlus Diagnostics, AZSense, BD, BG Medicine, BioLegend, bioMérieux, Bio-Rad Laboratories, BODITECH MED, CAVADIS, Cisbio Bioassays, Creative Diagnostics, Critical Diagnostics, Cruinn Medical, DiaDexus, Enzo Life Sciences, Lepu Medical, LifeSign, LSI Medience, Merck, Monobind, Myriad RBM, NeoClone, NOWDiagnostics, Olink, Randox Laboratories, Response Biomedical, Signosis, Thermo Fisher Scientific, Tosoh Europe, Trinity Biotech, Trivitron Healthcare, and Wondfo.

Market Reports Center © Copyright 2017 All rights reserved.

wire transfer
ssl